📣 VC round data is live. Check it out!
- Public Comps
- Oryzon Genomics
Oryzon Genomics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Oryzon Genomics and similar public comparables like Immuneering, Panacea Biotec, Prelude Therapeutics, IMBiologics and more.
Oryzon Genomics Overview
About Oryzon Genomics
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
Founded
2000
HQ

Employees
40
Website
Financials (LTM)
EV
$253M
Valuation Multiples
Start free trialOryzon Genomics Financials
Oryzon Genomics reported last 12-month revenue of $3M and negative EBITDA of ($10M).
In the same LTM period, Oryzon Genomics generated $3M in gross profit, ($10M) in EBITDA losses, and had net loss of ($7M).
Revenue (LTM)
Oryzon Genomics P&L
In the most recent fiscal year, Oryzon Genomics reported revenue of - and EBITDA of ($6M).
Oryzon Genomics is unprofitable as of last fiscal year, with gross margin of -, EBITDA margin of -, and net margin of -.
Financial data powered by Morningstar, Inc.
Oryzon Genomics Stock Performance
Oryzon Genomics has current market cap of $278M, and enterprise value of $253M.
Market Cap Evolution
Oryzon Genomics' stock price is $3.58.
Oryzon Genomics share price decreased by 2.3% in the last 30 days, and increased by 16.7% in the last year.
Oryzon Genomics has an EPS (earnings per share) of $-0.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $253M | $278M | 0.3% | -2.3% | 9.9% | 16.7% | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialOryzon Genomics Valuation Multiples
Oryzon Genomics trades at 78.6x EV/Revenue multiple, and (25.5x) EV/EBITDA.
EV / Revenue (LTM)
Oryzon Genomics Financial Valuation Multiples
As of June 3, 2026, Oryzon Genomics has market cap of $278M and EV of $253M.
Oryzon Genomics has a P/E ratio of (38.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Oryzon Genomics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Oryzon Genomics Margins & Growth Rates
Oryzon Genomics grew EBITDA by 100% in the last fiscal year.
Oryzon Genomics Margins
Oryzon Genomics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Oryzon Genomics Operational KPIs
Oryzon Genomics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Oryzon Genomics Competitors
Oryzon Genomics competitors include Immuneering, Panacea Biotec, Prelude Therapeutics, IMBiologics, Santhera Pharma, Zentalis Pharma, Eledon Pharmaceuticals, Surrozen, SAB Bio and Organogenesis.
Most Oryzon Genomics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (2.1x) | - | |||
| 3.9x | - | 79.5x | - | |||
| 17.8x | 11.3x | (2.1x) | (2.0x) | |||
| - | 27.6x | - | - | |||
| 3.2x | 2.9x | (7.8x) | (11.9x) | |||
| - | - | (0.7x) | (0.7x) | |||
| - | - | (2.0x) | - | |||
| 48.5x | 35.8x | (4.1x) | - | |||
This data is available for Pro users. Sign up to see all Oryzon Genomics competitors and their valuation data. Start Free Trial | ||||||
Oryzon Genomics VC Funding History
Before going public, Oryzon Genomics raised $19M in total equity funding, across 1 round.
Last private valuation of Oryzon Genomics was $110M, after raising $19M in October 2015.
Oryzon Genomics Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Oryzon Genomics
| When was Oryzon Genomics founded? | Oryzon Genomics was founded in 2000. |
| Where is Oryzon Genomics headquartered? | Oryzon Genomics is headquartered in Spain. |
| How many employees does Oryzon Genomics have? | As of today, Oryzon Genomics has over 40 employees. |
| Is Oryzon Genomics publicly listed? | Yes, Oryzon Genomics is a public company listed on Bolsa de Madrid. |
| What is the stock symbol of Oryzon Genomics? | Oryzon Genomics trades under ORY ticker. |
| When did Oryzon Genomics go public? | Oryzon Genomics went public in 2015. |
| Who are competitors of Oryzon Genomics? | Oryzon Genomics main competitors include Immuneering, Panacea Biotec, Prelude Therapeutics, IMBiologics, Santhera Pharma, Zentalis Pharma, Eledon Pharmaceuticals, Surrozen, SAB Bio, Organogenesis. |
| What is the current market cap of Oryzon Genomics? | Oryzon Genomics' current market cap is $278M. |
| What is the current revenue of Oryzon Genomics? | Oryzon Genomics' last 12 months revenue is $3M. |
| What is the current revenue growth of Oryzon Genomics? | Oryzon Genomics revenue growth (NTM/LTM) is 295%. |
| What is the current EV/Revenue multiple of Oryzon Genomics? | Current revenue multiple of Oryzon Genomics is 78.6x. |
| Is Oryzon Genomics profitable? | No, Oryzon Genomics is not profitable. |
| What is the current EBITDA of Oryzon Genomics? | Oryzon Genomics has negative EBITDA and is not profitable. |
| What is Oryzon Genomics' EBITDA margin? | Oryzon Genomics' last 12 months EBITDA margin is (308%). |
| What is the current EV/EBITDA multiple of Oryzon Genomics? | Current EBITDA multiple of Oryzon Genomics is (25.5x). |
| What is the current FCF of Oryzon Genomics? | Oryzon Genomics' last 12 months FCF is ($12M). |
| What is Oryzon Genomics' FCF margin? | Oryzon Genomics' last 12 months FCF margin is (374%). |
| What is the current EV/FCF multiple of Oryzon Genomics? | Current FCF multiple of Oryzon Genomics is (21.0x). |
| How many companies Oryzon Genomics has acquired to date? | Oryzon Genomics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Oryzon Genomics has invested to date? | Oryzon Genomics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Oryzon Genomics
Lists including Oryzon Genomics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.